AstraZeneca’s Crestor to be exposed to cutthroat competition

AstraZeneca (AZ)’s Crestor (rosuvastatin) will not be as stable as before with a growing number of pharmaceutical companies poising to enter a 50 billion Crestor market.

A total of 60 pharmaceutical manufacturers are expected to release the first generic version of Crestor, one of AZ flagship products for treatment of hyperlipidemia, as the re-examination period of this medicine expired las...